NasdaqGM:IOVABiotechs
Evaluating Iovance Biotherapeutics (IOVA) After Q1 Results And Amtagvi Adoption Update
Iovance Biotherapeutics (IOVA) is back in focus after first quarter 2026 results showed revenue of US$71.43 million, a reduced net loss, and management commentary centered on Amtagvi adoption and long term growth plans.
See our latest analysis for Iovance Biotherapeutics.
The stock has pulled back recently, with a 1-day share price return of 3.78% down and a 7-day share price return of 10.55% down. However, the 90-day share price return of 36.92% and 1-year total shareholder return of 98.88%...